Utilizing our new platform, we identified a novel senolytic compound that deleted p16Ink4a+ cells, reduced fibrotic burden in a murine model of lung fibrosis, and preferentially targeted p16Ink4a+ fibroblasts from human IPF lung samples. This evidence concerns the gene CDKN2A and idiopathic pulmonary fibrosis.